.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Moodys
Covington
US Army
Argus Health
Fish and Richardson
Julphar
UBS
Citi

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
Abstract:The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction.
Inventor(s): Emmick; Jeffrey T. (Plainfield, IN), Ferguson; Kenneth M. (Bothell, WA), Pullman; William E. (Carmel, IN), Whitaker; John S. (Woodinvill, WA)
Assignee: Lilly Icos, LLC. (Wilmington, DE)
Filing Date:Apr 26, 2000
Application Number:09/558,911
Claims:1. A method of treating sexual dysfunction in an individual suffering from a retinal disease comprising administering an oral dosage form comprising about 1 to about 20 mg of a selective PDE5 inhibitor having (i) at least a 100-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE6, (ii) at least 1000-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE1c, (iii) an IC.sub.50 less than 10 nM, and (iv) a sufficient bioavailability to be effective in about 1 to about 20 mg unit oral dosages.

2. The method of claim 1 wherein the retinal disease is diabetic retinopathy.

3. The method of claim 1 wherein the retinal disease is retinitis pigmentosa.

4. A method of treating sexual dysfunction in an individual suffering from a condition selected from the group consisting of class 1 congestive heart failure, a myocardial infarction within 90 days before onset of the sexual dysfunction treatment, and combinations thereof comprising administering an oral dosage from comprising about 1 to about 20 mg of a selective PDE5 inhibitor having (i) at least a 100-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE6, (ii) at least 1000-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE1c, (iii) an IC50 less than 10 nM, and (iv) a sufficient bioavailability to be effective in about 1 to about 20 mg unit oral dosages.

5. The method of claims 1 or 4 wherein the oral dosage form comprises about 5 mg, about 10 mg, or about 20 mg, of a selective PDE5 inhibitor.

6. The method of claim 1 or 4 wherein the maximum dosage of the selective PDE5 inhibitor is about 20 mg per 24-hour period.

7. The method of claim 1 or 4 wherein the selective PDE5 inhibitor has the structure ##STR15##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Cipla
Argus Health
AstraZeneca
Mallinckrodt
Deloitte
UBS
Moodys
Boehringer Ingelheim
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot